Dynavax (DVAX) Announces Acceptance of Two Data Abstracts for SD-101 in Combination with KEYTRUDA at AACR Meeting
Tweet Send to a Friend
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that data from an ongoing Phase 1b/2 study investigating SD-101, Dynavax's intratumoral TLR9 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
